Development and Validation of test for Gastro-esophageal Reflux with Aspiration

Information

  • Research Project
  • 8591417
  • ApplicationId
    8591417
  • Core Project Number
    R43HL120427
  • Full Project Number
    1R43HL120427-01
  • Serial Number
    120427
  • FOA Number
    PA-12-088
  • Sub Project Id
  • Project Start Date
    8/5/2013 - 11 years ago
  • Project End Date
    4/30/2017 - 7 years ago
  • Program Officer Name
    HARABIN, ANDREA L
  • Budget Start Date
    8/5/2013 - 11 years ago
  • Budget End Date
    4/30/2017 - 7 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/5/2013 - 11 years ago
Organizations

Development and Validation of test for Gastro-esophageal Reflux with Aspiration

DESCRIPTION (provided by applicant): Although recurrent microaspiration of refluxed gastric fluid (GER with microaspiration) is suspected in the onset and course of many diseases of the lungs and airways, the lack of a non-invasive, direct test for its occurrence has hampered research on its importance. Complicating assessment is its nocturnal occurrence, when sleep interferes with protective reflexes. The tests currently available, esophageal manometry and 24h pH monitoring, or scintigraphy, are expensive, technically difficult and indirect, or involve radioactive material. We have identified two compounds poorly absorbed systemically after ingestion; both are approved for human use and have few side effects. One is well absorbed from the lungs and airways and excreted in urine. The other is not absorbed from the lungs and airways, but can be prepared in monodisperse insoluble particles. We accordingly propose to examine whether overnight oral administration of the first drug results in greater quantities being detected in urine from 10 patients thought to have recurrent GER with microaspiration than from 5 healthy controls. We also propose to examine in the same subjects whether administration of the second substance as a suspension of particles results in different quantities being detected in sputum collected overnight and induced the following morning. We will examine the concordance of the findings when the drugs are given together - the particles of the second substance suspended in a solution of the first. If this pilot study is promising, we will propose Phase II studies to refine the methods and examine them in larger numbers of subjects.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    339824
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:339824\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARADIGM CORPORATION
  • Organization Department
  • Organization DUNS
    792998783
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    945453720
  • Organization District
    UNITED STATES